GSTT1 null and MPO -463G>A Polymorphisms and Carboplatin Toxicity in an Indian Population |
Bag, Arundhati
(Institute of Allied Health (Paramedical) Services, Education and Training)
Pant, Nirdosh Kumar (Swami Ram Cancer Hospital and Research Center) Jeena, Lalit Mohan (Institute of Allied Health (Paramedical) Services, Education and Training) Bag, Niladri (Department of Plantation Management and Studies, Sikkim University) Jyala, Narayan Singh (Department of Biochemistry, Govt. Medical College) |
1 | Bag A, Rawat S, Pant NK, et al (2012). Cancer patterns in Nainital and adjoining districts of Uttarakhand: A one year survey. J Nat Sci Biol Med, 3, 186-8. DOI ScienceOn |
2 | Bag A, Upadhyay S, Jeena LM, Pundir P, Jyala NS (2013). GSTT1 null genotype distribution in the Kumaun region of northern India. Asian Pac J Cancer Prev, 14, 87-9. DOI ScienceOn |
3 | Barahmani N, Carpentieri S, Li XN, et al (2009). Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro Oncol, 11, 292-300. DOI ScienceOn |
4 | Cheng CF, Juan SH, Chen JJ, et al (2008). Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. Apoptosis, 13, 883-94. DOI |
5 | Di Pietro G, Magno LAV, Rios-Santos F (2010) Glutathione S-transferases: an overview in cancer research. Expert Opin Drug Metab Toxicol, 6, 153-70. DOI ScienceOn |
6 | Donnelly JG (2004). Pharmacogenetics in cancer chemotherapy: balancing toxicity and response. Ther Drug Monit, 26, 231-5. DOI ScienceOn |
7 | Erculj N, Kovac V, Hmeljak J, Dolzan V (2012). The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma. Ann Oncol, 23, 961-7. DOI ScienceOn |
8 | Hayes JD, Pulford DJ (1995). The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol, 30, 445-600. DOI ScienceOn |
9 | He C, Tamimi RM, Hankinson SE, Hunter DJ, Han J (2009). A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk. Breast Cancer Res Treat, 113, 585-94. DOI ScienceOn |
10 | Husain K, Whitworth C, Somani SM, Rybak LP (2001). Carboplatin-induced oxidative stress in rat cochlea. Hear Res, 159, 14-22. DOI ScienceOn |
11 | Klebanoff SJ (1999). Myeloperoxidase. Proc Assoc Am Physicians, 111, 383-9. |
12 | Lin H, Sue YM, Chou Y, et al (2010). Activation of a nuclear factor of activated T-lymphocyte-3 (NFAT3) by oxidative stress in carboplatin-mediated renal apoptosis. Br J Pharmacol, 161, 1661-76. DOI ScienceOn |
13 | Ma Q, Lu AY (2011) Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev, 63, 437-59. DOI ScienceOn |
14 | Marsh S, Paul J, King CR, et al (2007). Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol, 25, 4528-35. DOI ScienceOn |
15 | O?dwyer PJ, Johnson SW, Hamilton TC (1997). Cisplatin and its analogues. In 'Cancer: Principles and Practices of oncology', Eds DeVita VT Jr., Hellman S, Rosenberg SA. Lippincott-Raven, Phila, 418-32. |
16 | Millward MJ, Boyer MJ, Lehnert M, et al (2003). Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol, 14, 449-54. DOI ScienceOn |
17 | Moyer AM, Sun Z, Batzler AJ, et al (2010). Glutathione pathway genetic polymorphisms and lung cancer survival after platinum- based chemotherapy. Cancer Epidemiol Biomarkers Prev, 19, 811-21. DOI ScienceOn |
18 | Nakamura Y (2008). Pharmacogenomics and Drug Toxicity. N Engl J Med, 359, 856-8. DOI ScienceOn |
19 | Ochoa L, Waypa G, Mahoney JR Jr, Rodriguez L, Minnear FL (1997). Contrasting effects of hypochlorous acid and hydrogen peroxide on endothelial permeability: prevention with cAMP drugs. Am J Respir Crit Care Med, 156, 1247-55. DOI ScienceOn |
20 | Palma JP, Aggarwal SK (1994). Cisplatin and carboplatin mediated release of cytolytic factors in murine peritoneal macrophages in vitro. Anticancer Drugs, 5, 615-22. DOI |
21 | Piedrafita FJ, Molander RB, Vansant G, et al (1996). An Alu element in the myeloperoxidase promoter contains a composite SP1- thyroid hormone-retinoic acid response element. J Biol Chem, 271, 14412-20. DOI ScienceOn |
22 | Sambrook J, Fritsch E, Maniatis T (1989). Molecular cloning- a laboratory manual. Cold Spring Harbor Laboratory Press, NY, 1989. |
23 | Soo RA, Kawaguchi T, Loh M, et al (2012). Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. Future Oncol, 8, 451-62. DOI ScienceOn |
24 | Thorn CF, Ji Y, Weinshilboum RM, Altman RB, Klein TE (2012). PharmGKB summary: very important pharmacogene information for GSTT1. Pharmacogenet Genomics, 22, 646-51. DOI |
25 | Undevia SD, Gomez-Abuin G, Ratain MJ (2005). Pharmacokinetic variability of anticancer agents. Nat Rev Cancer, 5, 447-58. DOI ScienceOn |